0001437749-21-025788.txt : 20211109 0001437749-21-025788.hdr.sgml : 20211109 20211109082900 ACCESSION NUMBER: 0001437749-21-025788 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20211109 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20211109 DATE AS OF CHANGE: 20211109 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Aravive, Inc. CENTRAL INDEX KEY: 0001513818 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 264106690 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36361 FILM NUMBER: 211390007 BUSINESS ADDRESS: STREET 1: RIVER OAKS TOWER STREET 2: 3730 KIRBY DRIVE, SUITE 1200 CITY: HOUSTON STATE: TX ZIP: 77098 BUSINESS PHONE: 936-355-1910 MAIL ADDRESS: STREET 1: RIVER OAKS TOWER STREET 2: 3730 KIRBY DRIVE, SUITE 1200 CITY: HOUSTON STATE: TX ZIP: 77098 FORMER COMPANY: FORMER CONFORMED NAME: Versartis, Inc. DATE OF NAME CHANGE: 20110223 8-K 1 arav20211108_8k.htm FORM 8-K arav20211108_8k.htm
false 0001513818 0001513818 2021-11-09 2021-11-09
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 
 
FORM 8-K
 
 
CURRENT REPORT
 
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): November 9, 2021
 
 
Aravive, Inc.
(Exact name of Registrant as Specified in Its Charter)
 
 
Delaware 001-36361 26-4106690
(State or Other Jurisdiction (Commission (IRS Employer
of Incorporation) File Number) Identification No.)
 
River Oaks Tower
3730 Kirby Drive, Suite 1200
Houston, Texas 77098
(Address of principal executive offices)
 
(936) 355-1910
(Registrant’s telephone number, including area code)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):
 
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Securities registered pursuant to Section 12(b) of the Act:
 
    Trading    
Title of each class   Symbol(s)   Name of each exchange on which registered
Common stock, par value $0.0001 per share   ARAV   Nasdaq Global Select Market
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
 
Emerging growth company ☐
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
 
 
 
 
 
Item 7.01.   Regulation FD Disclosure.
 
On November 9, 2021, Aravive, Inc. (the “Company”) issued a press release announcing that an abstract titled “A Phase 1b/2 randomized study of AVB-S6-500 in combination with cabozantinib versus cabozantinib alone in patients with advanced clear cell renal cell carcinoma who have received front-line treatment” that it had submitted to the Society for Immunotherapy of Cancer (SITC) in connection with its 36th Annual Meeting was published.
 
As of July 21, 2021, seven patients received at least one dose of batiraxcept (AVB-500) 15 mg/kg in combination with cabozantinib, six patients were ongoing treatment, and five patients were evaluable for efficacy. No dose-limiting toxicities were observed in the first three evaluable patients. Trough levels at cycle 1 day 15 were above the minimal efficacious concentration identified from the Company’s model informed drug development approach, and serum GAS6 levels were suppressed prior to cycle 2 day 1. A best overall response of partial response was observed in 3 of 5 patients (60%, unconfirmed as of July 21, 2021), based on investigator assessment, RECIST v 1.1 criteria. In addition, all patients demonstrated tumor decrease from baseline.
 
A copy of the Abstract is furnished to this Current Report on Form 8-K as Exhibit 99.2. The press release and Abstract are being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing. The press release furnished as Exhibit 99.1 to this Current Report on Form 8-K includes “safe harbor” language pursuant to the Private Securities Litigation Reform Act of 1995, as amended, indicating that certain statements contained therein are “forward-looking” rather than historical.
 
The furnishing of the attached Abstract is not an admission as to the materiality of any information therein. The information contained in the Abstract is summary information that is intended to be considered in the context of more complete information included in the Company’s filings with the Securities and Exchange Commission (the “SEC”) and other public announcements that the Company has made and may make from time to time by press release or otherwise. The Company undertakes no duty or obligation to update or revise the information contained in this Current Report on Form 8-K, although it may do so from time to time as its management believes is appropriate. Any such updating may be made through the filing of other reports or documents with the SEC, through press releases or through other public disclosures.
 
Item 8.01 Other Information
 
On November 9, 2021,  the Company issued a press release announcing that an abstract titled “A Phase 1b/2 randomized study of AVB-S6-500 in combination with cabozantinib versus cabozantinib alone in patients with advanced clear cell renal cell carcinoma who have received front-line treatment” that it had submitted to the Society for Immunotherapy of Cancer (SITC) in connection with its 36th Annual Meeting was published.
 
As of July 21, 2021, seven patients received at least one dose of batiraxcept (AVB-500) 15 mg/kg in combination with cabozantinib, six patients were ongoing treatment, and five patients were evaluable for efficacy. No dose-limiting toxicities were observed in the first three evaluable patients. Trough levels at cycle 1 day 15 were above the minimal efficacious concentration identified from the Company’s model informed drug development approach, and serum GAS6 levels were suppressed prior to cycle 2 day 1. A best overall response of partial response was observed in 3 of 5 patients (60%, unconfirmed as of July 21, 2021), based on investigator assessment, RECIST v 1.1 criteria. In addition, all patients demonstrated tumor decrease from baseline.   
 
Item 9.01.   Financial Statements and Exhibits.
 
(d) Exhibits.
 
The following exhibit is furnished to this Current Report on Form 8-K:
 
Exhibit
Number
  
Description
99.1   Press Release dated November 9, 2021
99.2
  
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)
 
 
 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
Date: November 9, 2021
ARAVIVE, INC.
(Registrant)
   
   
 
By:
  
/s/ Gail McIntyre
 
Name:
  
Gail McIntyre
 
Title:
  
Chief Executive Officer
 
 
 EX-99.1 2 ex_304496.htm EXHIBIT 99.1 ex_304496.htm

Exhibit 99.1

 

logo.jpg

 

Aravive Announces Positive Preliminary Data from Phase 1b Trial Evaluating
Batiraxcept (AVB-500) in Combination with Cabozantinib in Clear Cell Renal Cell Carcinoma to

be Presented at 2021 Society for Immunotherapy of Cancer Annual Meeting

 

3 of 5 (60%) patients achieved a partial response
All 5 patients treated demonstrated tumor decrease from baseline

Batirxcept has been generally well-tolerated with no dose-limiting toxicities

Aravive to host conference call and webcast on November 12 at 8:30 a.m. ET to discuss updated data

 

Houston, TX, November 9, 2021 – Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing transformative, targeted therapeutics to treat life-threatening cancers, today announced that positive new data from the Phase 1b portion of its open-label Phase 1b/2 trial evaluating batiraxcept (AVB-500) in combination with cabozantinib in patients with clear cell renal cell carcinoma (ccRCC) will be presented at the Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting on November 13, 2021. The presentation will highlight interim safety, pharmacokinetic (PK), pharmacodynamic (PD), and clinical activity data.

 

“We are encouraged by the preliminary performance of batiraxcept in combination with cabozantinib in patients with clear cell renal cell carcinoma,” said Gail McIntyre, Ph.D., DABT, Chief Executive Officer of Aravive. “These results highlight the potential of batiraxcept to improve outcomes for patients with advanced kidney cancer. We look forward to sharing these new clinical data with the research and medical community at this year’s SITC Annual Meeting.”

 

As of July 21, 2021, seven patients received at least one dose of batiraxcept 15 mg/kg in combination with cabozantinib, six patients were ongoing treatment, and five patients were evaluable for efficacy. No dose-limiting toxicities were observed. Trough levels at cycle 1 day 15 were above the minimal efficacious concentration identified from the Company’s model informed drug development approach, and serum GAS6 levels were suppressed prior to cycle 2 day 1. A best overall response of partial response was observed in 3 of 5 patients (60%, unconfirmed as of July 21, 2021), based on investigator assessment, RECIST v 1.1 criteria. In addition, all patients demonstrated tumor decrease from baseline.

 

Aravive’s presentation at the SITC Annual Meeting will include updated safety, PK, PD, and clinical activity data from a larger set of patients treated with batiraxcept 15 mg/kg in combination with cabozantinib as of October 16, 2021.

 

Poster Presentation Details

 

Title: A Phase 1b/2 randomized study of AVB-S6-500 in combination with cabozantinib versus cabozantinib alone in patients with advanced clear cell renal cell carcinoma who have received front-line treatment
   
Presenter: Reshma Rangwala, M.D., Ph.D., Chief Medical Officer of Aravive
   
Date: November 13, 2021
   
Time: 7:00 AM – 8:30 PM ET
   
Location: Hall E

 

 
 

 

For additional information, please visit the SITC 36th Annual Meeting website: https://www.sitcancer.org/2021/home.

 

Conference Call Information

Aravive will host a conference call and webcast on November 12, 2021 at 8:30 a.m. ET to discuss these clinical data. The conference call may be accessed by dialing (877) 423-9813 (domestic) and (201) 689-8573 (international) and referring to conference ID 13724115. A webcast of the conference call will be available in the Investors section of the Aravive website at https://ir.aravive.com/. The archived webcast will be available on Aravive’s website after the conference call.

 

About the Batiraxcept (AVB-500) Phase 1b/2 ccRCC Trial

Aravive initiated the Phase 1b portion of the Phase 1b/2 trial of batiraxcept in ccRCC in March 2021. The Phase 1b portion of the clinical trial, a dose escalation study, is expected to enroll approximately 18 patients in three dosing arms (15 mg/kg, 20 mg/kg and 25 mg/kg) to evaluate tolerability, pharmacokinetics, pharmacodynamics, and clinical activity of batiraxcept in combination with cabozantinib. The controlled, randomized, open-label Phase 2 portion of the clinical trial is expected to enroll approximately 45 patients and investigate the recommended batiraxcept dose identified during the Phase 1b portion of the clinical trial in combination with cabozantinib versus cabozantinib alone. The primary endpoint is progression-free survival. The trial is enrolling patients with advanced ccRCC who have progressed on front-line treatment. The Phase 1b/2 trial is listed on clinicaltrials.gov NCT04300140.

 

About Batiraxcept (AVB-500)

Batiraxcept is a therapeutic recombinant fusion protein that has been shown to neutralize GAS6 activity by binding to GAS6 with very high affinity in preclinical models. In doing so, batiraxcept selectively inhibits the GAS6-AXL signaling pathway, which is upregulated in multiple cancer types including ovarian, renal and pancreatic cancer. In preclinical studies, GAS6-AXL inhibition has shown anti-tumor activity in combination with a variety of anticancer therapies, including radiation therapy, immuno-oncology agents, and chemotherapeutic drugs that affect DNA replication and repair. Increased expression of AXL and GAS6 in tumors has been correlated with poor prognosis and decreased survival and has been implicated in therapeutic resistance to conventional chemotherapeutics and targeted therapies. Batiraxcept is currently being evaluated in multiple clinical trials and has been granted Fast Track designation by the U.S. Food and Drug Administration and orphan drug designation by the European Commission in platinum resistant recurrent ovarian cancer.

 

About Aravive

Aravive, Inc. is a clinical-stage oncology company developing transformative, targeted therapeutics to treat life-threatening cancers. The Company is currently evaluating its lead therapeutic, batiraxcept (AVB-500), in a registrational Phase 3 trial in platinum resistant ovarian cancer, a Phase 1b/2 trial in second line plus, clear cell renal cell carcinoma, and a Phase 1b/2 trial in first-line treatment of pancreatic adenocarcinoma. The Company is based in Houston, Texas and received a Product Development Award from the Cancer Prevention & Research Institute of Texas (CPRIT) in 2016. For more information, please visit www.aravive.com.

 

 
 

 

Forward-Looking Statements

This communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases, forward-looking statements can be identified by terminology such as "may," "should," "potential," "continue," "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions and includes statements regarding the potential of batiraxcept (AVB-500) to improve outcomes for patients with advanced kidney cancer. Forward-looking statements are based on current beliefs and assumptions, are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results to differ materially from those contained in any forward-looking statement as a result of various factors, including, but not limited to, risks and uncertainties related to: the data from patients treated in the future with batiraxcept being consistent with the results reported, the ability to enroll the expected number of patients, the impact of COVID-19 on the Company's clinical strategy, clinical trials, supply chain and fundraising, the Company's ability to expand development into additional indications, the Company's dependence upon batiraxcept, batiraxcept’s ability to have favorable results in clinical trials and ISTs, the clinical trials of batiraxcept having results that are as favorable as those of preclinical and clinical trials, the ability to receive regulatory approval, potential delays in the Company's clinical trials due to regulatory requirements or difficulty identifying qualified investigators or enrolling patients especially in light of the COVID-19 pandemic; the risk that batiraxcept may cause serious side effects or have properties that delay or prevent regulatory approval or limit its commercial potential; the risk that the Company may encounter difficulties in manufacturing batiraxcept; if batiraxcept is approved, risks associated with its market acceptance, including pricing and reimbursement; potential difficulties enforcing the Company's intellectual property rights; the Company's reliance on its licensor of intellectual property and financing needs. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the risk factors included in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2020, recent Current Reports on Form 8-K and subsequent filings with the SEC. Except as required by applicable law, the Company undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.

 

Contacts:

Media:

Aulani Capuchin, Real Chemistry

acapuchin@realchemistry.com

(559) 355-2673

 

Investors:

Luke Heagle, Real Chemistry

lheagle@realchemistry.com

(910) 619-5764

 

 
 EX-99.2 3 ex_304555.htm EXHIBIT 99.2 ex_304555.htm

Exhibit 99.2

 

 

A Phase 1b/2 randomized study of AVB-S6-500 in combination with cabozantinib versus cabozantinib alone in patients with advanced clear cell renal cell carcinoma who have received front-line treatment (NCT04300140)

 

Background

 

In clear cell renal cell carcinoma (ccRCC) the constitutive expression of hypoxia induced factor 1-α leads to increased expression of AXL. AXL overexpression has been associated with the development of resistance to VEGF inhibitors and suppression of the innate immune response through inhibition of macrophage-driven inflammation. AVB-S6-500 (AVB-500) is recombinant fusion protein dimer containing an extracellular region of human AXL combined with the human immunoglobulin G1 heavy chain (Fc), which demonstrates highly potent, specific AXL inhibition. In a mouse ccRCC xenograft model, AVB-500 showed significantly more tumor reduction in combination with pazopanib versus pazopanib alone. In a Ph1b study of AVB-500 plus chemotherapy in platinum-resistant ovarian cancer (NCT03639246), no dose limiting toxicity (DLT) or treatment discontinuation due to adverse events was observed. The recommended phase 2 dose (RP2D) of 15 mg/kg was established by a model-informed drug development (MIDD) approach.

 

Trial design

 

The P1b portion of this trial is a 3+3 dose escalation study to evaluate safety, pharmacokinetics, and pharmacodynamics of AVB‑500 in combination with cabozantinib 60 mg daily in patients with advanced ccRCC. Dose levels of AVB-500 evaluated include 15, 20, and 25 mg/kg every two weeks. The primary objective is to evaluate safety and tolerability. Secondary objectives include identification of the RP2D of AVB-500 and clinical activity. Key eligibility criteria include clear cell histology RCC and at least one prior line of therapy administered in the advanced or metastatic setting.

 

Results

 

As of July 21, 2021, seven patients have received at least one dose of AVB-500 15 mg/kg and cabozantinib, with six patients ongoing treatment. No DLTs were observed. Trough levels at C1D15 were above the minimally efficacious concentration (MEC) identified from MIDD and serum GAS6 (AXL ligand) levels were suppressed prior to C2D1. Partial responses were observed in 3 of 5 patients (Table 1); all patients demonstrated tumor decrease from baseline. 

 

 
 

 

Table 1: Preliminary Clinical Activity in NCT04300140

 

 

Prior lines of therapy in the

advanced/metastatic setting

# Cycles

completed

Best overall

response

102-001

1)       Nivolumab/ipilimumab

2)       Axitinib

3) 

        

1.5,

discontinued

study

SD

102-002

1)       Pazopanib

2)       Pembrolizumab/axitinib

 

3, ongoing

SD

103-001

1)       Nivolumab/ipilimumab

 

4, ongoing

PR, unconfirmed

105-002

1)       Sunitinib 2) Nivolumab

 

2, ongoing

PR, unconfirmed

107-002

1)       Pazopanib

2)       Everolimus

3)       Axitinib

4)       Nivolumab/ipilimumab

5)       Pembrolizumab/axitinib (Best response to therapy PD)

 

2, ongoing

PR, unconfirmed

 

 

Summary:

 

AVB-500 in combination with cabozantanib demonstrates promising preliminary clinical activity and tolerability in patients with ccRCC. AVB-500 15 mg/kg is the presumptive RP2D with C1D15 AVB-500 troughs consistently above MECs observed in the Ph1b OC trial. Safety, PK/ PD and clinical activity will be updated at the time of presentation.

 

 
 EX-101.SCH 4 arav-20211109.xsd XBRL TAXONOMY EXTENSION SCHEMA 000 - Document - Document And Entity Information link:calculationLink link:definitionLink link:presentationLink EX-101.DEF 5 arav-20211109_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 6 arav-20211109_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity [Domain] Legal Entity [Axis] Document Information [Line Items] Document Information [Table] Document, Type Document, Period End Date Entity, Registrant Name Entity, Incorporation, State or Country Code Entity, File Number Entity, Tax Identification Number Entity, Address, Address Line One Entity, Address, Address Line Two Entity, Address, City or Town Entity, Address, State or Province Entity, Address, Postal Zip Code City Area Code Local Phone Number Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security Trading Symbol Security Exchange Name Entity, Emerging Growth Company Amendment Flag Entity, Central Index Key EX-101.PRE 7 arav-20211109_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 8 logo.jpg begin 644 logo.jpg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end XML 9 arav20211108_8k_htm.xml IDEA: XBRL DOCUMENT 0001513818 2021-11-09 2021-11-09 false 0001513818 8-K 2021-11-09 Aravive, Inc. DE 001-36361 26-4106690 River Oaks Tower 3730 Kirby Drive, Suite 1200 Houston TX 77098 936 355-1910 false false false false Common stock ARAV NASDAQ false XML 10 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Document And Entity Information
Nov. 09, 2021
Document Information [Line Items]  
Entity, Registrant Name Aravive, Inc.
Document, Type 8-K
Document, Period End Date Nov. 09, 2021
Entity, Incorporation, State or Country Code DE
Entity, File Number 001-36361
Entity, Tax Identification Number 26-4106690
Entity, Address, Address Line One River Oaks Tower
Entity, Address, Address Line Two 3730 Kirby Drive, Suite 1200
Entity, Address, City or Town Houston
Entity, Address, State or Province TX
Entity, Address, Postal Zip Code 77098
City Area Code 936
Local Phone Number 355-1910
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common stock
Trading Symbol ARAV
Security Exchange Name NASDAQ
Entity, Emerging Growth Company false
Amendment Flag false
Entity, Central Index Key 0001513818
EXCEL 11 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 12 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 13 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 1 96 1 false 0 0 false 0 false false R1.htm 000 - Document - Document And Entity Information Sheet http://www.arav.com/20211109/role/statement-document-and-entity-information Document And Entity Information Cover 1 false false All Reports Book All Reports arav20211108_8k.htm arav-20211109.xsd arav-20211109_def.xml arav-20211109_lab.xml arav-20211109_pre.xml ex_304496.htm ex_304555.htm http://xbrl.sec.gov/dei/2021 true false JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "arav20211108_8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "definitionLink": { "local": [ "arav-20211109_def.xml" ] }, "inline": { "local": [ "arav20211108_8k.htm" ] }, "labelLink": { "local": [ "arav-20211109_lab.xml" ] }, "presentationLink": { "local": [ "arav-20211109_pre.xml" ] }, "schema": { "local": [ "arav-20211109.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/sic/2021/sic-2021.xsd", "https://xbrl.sec.gov/currency/2021/currency-2021.xsd", "https://xbrl.sec.gov/exch/2021/exch-2021.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" ] } }, "elementCount": 27, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "arav", "nsuri": "http://www.arav.com/20211109", "report": { "R1": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "arav20211108_8k.htm", "contextRef": "d20218K", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000 - Document - Document And Entity Information", "role": "http://www.arav.com/20211109/role/statement-document-and-entity-information", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "arav20211108_8k.htm", "contextRef": "d20218K", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.arav.com/20211109/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.arav.com/20211109/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.arav.com/20211109/role/statement-document-and-entity-information" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.", "label": "Document Information [Table]" } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document, Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.arav.com/20211109/role/statement-document-and-entity-information" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document, Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.arav.com/20211109/role/statement-document-and-entity-information" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity, Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.arav.com/20211109/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity, Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.arav.com/20211109/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity, Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.arav.com/20211109/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity, Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.arav.com/20211109/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity, Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.arav.com/20211109/role/statement-document-and-entity-information" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity, Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.arav.com/20211109/role/statement-document-and-entity-information" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.arav.com/20211109/role/statement-document-and-entity-information" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity, Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.arav.com/20211109/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity, File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.arav.com/20211109/role/statement-document-and-entity-information" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity, Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.arav.com/20211109/role/statement-document-and-entity-information" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity, Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.arav.com/20211109/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity, Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.arav.com/20211109/role/statement-document-and-entity-information" ], "xbrltype": "employerIdItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.arav.com/20211109/role/statement-document-and-entity-information" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.arav.com/20211109/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.arav.com/20211109/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.arav.com/20211109/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.arav.com/20211109/role/statement-document-and-entity-information" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.arav.com/20211109/role/statement-document-and-entity-information" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.arav.com/20211109/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.arav.com/20211109/role/statement-document-and-entity-information" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.arav.com/20211109/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 17 0001437749-21-025788-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001437749-21-025788-xbrl.zip M4$L#!!0 ( )U#:5.N N4_;@, "<. 1 87)A=BTR,#(Q,3$P.2YX MGY7%N0&M!%*SI)L-$X(2*YR(5>SY,=5^N[J M_7R>$&.9S%FA),P2J9+SL]>O3M^DZ2>0H)F%G"SNR?6ZECGH"U4"^::T905) M29;1"3T:'V4DFQZ]G1Z?D&^?T]31[TP^-7P-)2.H09KIW4(78I:LK:VFE-[> MWH[82^/0[8C/[\?'GE]^[ A9"_^^#99#*A?C5 MI9*R+ON%Y%93>U\!15"**-""!YZQE>Y8GF& CU;JAKH5'X0 ?20F]M0M+YCI M/!T@)Y;B +F-Q;2[G]!F,4!S$/VB<2'2S%4MK;[O![>+$<$(OB,<@L<[UUIC MTNW:NEV-*'#'U_UPMQ)!F68W4?359D?I<39"TPG=6\.$:E5@JL'*W?AA.@JM(Y93,7$J MLK>'J.B_?D.$;#._-,3]M>RZU'T"S$Z\'Z5N]+(0'.;^BWQ_5$,&YF(@.+,G MAP1[4XP&Q3K W6"?2#]1TP;9W::$CX/M;\KDL/QJX6YPN,]QL1WF]#:G^SI8 MPE8!'V2^P_M1;+8US*14UN\1I+"J$G*IW*=[;*?AQ?T.2^*; 7PVN"M<3[<, MM-*J FT%F.U'VV^PUK"<):[VIZ'N_RK88H2O4H \,A#7;U\XD0+%Y49>X+K; M/$L,QK2 )L3_TI$>NO3[)\3Q?GR?/]U5-,*&[]JIVIQ,TS(-Z4S/ MQN,QMO<7K8WMX3N9DP_>')EOS)W2![8Z\[6!_*L\\V/."EX7751;4HOH(\19 M]3S^X;D]8M#HH/S,@X)!^TM*VR 2MC!6,X[MH=4UIIT[:G=6OT* ,#Y->.;; M1^RJXBQY!B,*+ MZFJ6^#]14X$I@#VI3\)F!C7A7[HY MSCNW,$W]+%X2H?)KC\MKW9BAG9--_<7/OU!+ P04 " "=0VE3^MQH8N<$ M !F+@ %0 &%R878M,C R,3$Q,#E?9&5F+GAM;-5:78_:.!1]7VG_0YI] M#B&PTUU0:868:85VIH,&JJ[V96622[#JV,AQ!OCW:X>/84J<& :C[ LD\/$_=3C#]T54?4Y2"(VG0-#_MN7,A%EW?7RZ7C=64DP;CL0S1;/L[ MM+N%J]9([&\X!-_XF\8]]"CTLIUC@TZGX^>M>VB*BX R:.#__7 _#N>0( ]3 ME9-0<4EQ-\TOWK,0B3R1E1(<+4*=>3N8IRYY0!.L5[(:9#B9$' M]=]**6()PM1+()D"/Y-<88P+T\0)4+5*O$UGYS+5A+DLV;F,QL-L"MZ^OS/Y MED2REE^8H8R(MR?X=1P-W1W7GXFJGA!'SXV0)?D&%@3-CI]3E0M?@.Q%R#$, ML_Q [HZ>_,9B+3>&&>-)O@^\EJ"B>;M(.=>3 VDT2*688@6\EZ=;K*)J10T",N9F\CP)9DZ;+;,9 0V6.K1,X MMJ[)<2 /'_F$+?6/72WR&OSR%?K(1YP]X\VK7RE)#?P:3$=,EG7D'[PHW7[* MP)98JH'KB/AC[-9X6A6@Z_#%[A@YBB=&$(^5)CM?)E!5-O<)VR]FY6X5S M1&/0U*)E,*O/@+L$>"R3\86SI9C+>;1 =*U]")2B+?'LRTD=J8G]F:"X@%EA MN]6<#61G')&A7&&KOT"?+0U.Q^W%F>GST&%VY1WY:Y5-R0LA:CG"I[M MI\;6$#O?D9QQEI2_R+(J2T5V424BN+B(UT[*62J*[9B=FFL,2HE?^J*HTJ-A M!D;$BZKS=&TO,BI@)>Y(_ISIN2G$ZN!DW0<_#Y3J/'9YV"F^U14G9M%/"F^3 M=FSA&,AIU59.B?UCH*M=.UW5WI&!K-]K*NL$I\E Y4U-5>JL*@-)[VLJR M,M#W1TWU5=IB!MK^_-]H:YVLK5-O;3HCSN1!?:DZV)*T4OO.1%_]*A%3V\]$ M7?T*$[UY:**G?@5)N?UHHJE^U8B!=VDBK'X%2)7W::*J?C6(J6=JHJY^%J.:JO81%==ZPT#A]E$7OT*CA*;VD10 M_2H. X_[P$SU?](FP_[XN+^N/M1?F.65_P!02P,$% @ G4-I4Q1UJ) / M!@ :SX !4 !A3ZPR)-T'?,,@+TIA5;UH3SZ97OS^?SB\60 M)1? QB+%VTM_'=U:A>Q'$YR&'J'2DTC6DI&K3/WX"%'(E9%'=P$9(^0W;QWFR9^\H.U=!A>+ M+&YMC&.0X&<\0O+SY;EK5.SX,L*G>"S;]!@.<2(J5BDF#(_TVR6,%3:3571D M%<%[6<6ONFQ\.15L9"2=)KCEO[+.'F8$X@=ZYH+U:2U4WNF,1@BZ-@$V!J?&ESP5_]S"CG"WO(38S46FKDQ IS>R*F$(1;Y J P%#JU*0 MK*4!C*JY#B?::1&R3R3!7V?I$#,C48.*%:F('-T:.S4L6'RR3X9 M:DK\Q'H,OI/\-8?2AAK"7\/(7DKGH&PN;M85-$>+R5T=,J6VV>>F!QD/D[_) MM/0RN2SX-TC3&5U="NL>IY?&U>RZ-I?MUJ]$45'5:?O+/83*YE@!H0\) MB0@G=/Q%S#<8"1,-!>:@F@@<)K+=_ZTB6DLZ;7Z)=5#-$RMM[S$L4<.B=O6( M5KYPQYY&(^U9_WAP30S,"6WC()2]:$<:Y=I(B3L%HX*I4,\M%Z!TLVR&62U< MC)N\#IJ#M,[1R2OX80@R^ZSGZ(B!=D8;',W$0+<,VL,!X=JWL4PA=4>:O32V MZ5 B"$8H:/\V_!VMY=V.-2;KH(HG5AH^8*'\'Z3^,AV";F:A75^SU84,'Q(,1L+]#XSF/.)&&&F(5T:[QB61I]TRU";T=4]P[4XRM712KZ!6X;E MQD)-QZSPF';&<>GQ*PK&&$.WZFDP4Q=+O] MB>3_QRQ^^1]02P,$% @ G4-I4Y)U4_. ! -2\ !4 !A+E&6D6/3];Y-@,!DFB>^5 A49HJS ?;]@_J>//__TX5T0?,$%YDC@ MS)OMO.ER7628W[,<>V/&!:)>X$51V WC=AQY42]^W^O<>>/'()#5*2F^]^3/ M#)78 QI%J2[[_E*(52\,-YM-:SOCM,7X IIH=\(CVC_ 96DF3A7.P7?AOO $ MO6AZTU'8J-OMAJKT!"U)%1 :C<*_'D>3=(ES%)!":I)*+B7IE>KFB*5(*"$; MA^!I$?(J.,(">2N(XJ 3M;9EYI^$XXSB9SSWY/';<_*J1\312RMEN=(]BMK= M4*)"X"MPC@L19"Q=JQ-XJ $.:,YXH^#$GUL>1XWO=E:\&Q)4GBEZL; M$KL5Q$U)\A7%?G@:PXKC$BHIZ AN'-"2K)7Q[&G@K< 0IV=:4I:^&K'LNCS& M4XG3UH*]A!DFJG]YHN104L#%/P^J0PA[1$Y=433#M._KBO=,J P7QL\4^9], M1GB!Z+Z_P9:4%60T"$M\[@_/)?GQ+*9H1G$%L2;H[1A").($ JM*/A.X9:93 M:+Z&V7FQ929CS G+'HKL'M[#&DJ5.$O<]J']C!>D%!P5XBO*JZC5P:PR2V!M MY2O&5>A,Y 0V9.M"\-V097JB1K6L\OY,*/ZZSF>8:TE>0JPRFJ)MDLFY?D[V MBVX#O0:\5:Z#+(.EKCP)3MM$OMUKD+?BI M-_2)CSE[(?L,L9:D!GX+IF,&213]FZQJIY\ZL"66\L$-.$8:7E7%MG(J:)". ME_#EHYU@=!!+C/[D1$ *.V1YOBX.DUE5LE*+L\1MPBA)B8"OQT<(:DX0K2"F M!UEB->98J@ ?MNI[82KS?_XTGU<^S6;P;5@F9;G&_"JNVBJVGC9.UQ!DNRB> M38FHS.MU$$N,IAQ)ZV*RRV>L*O0JRRVK\[!-EZA88$TN6@>SN@8\Y)@O0(PO MG&W$$N)HA8J==A&H15OB.8"@SF1@?Z9H4<&LLMRJ9D/HC".:P!NV_0/KU=+@ M=-S.G9 !3SW&X0WN^VW?@Q)XCSG.1OLNM+:1LD04#^A,65^]E+(29WU?\/4I MHA!/+_R5UPT=$.$*<6FII$M"LV/M.6=YO9' FDP/:%X-_.T.O=&J8 9>BZ$, MT=N7P=PS.6KB4&!OC%2(W5*AQC SDJ/CAAQ7>U]& MXOSJDC@ZS\U(B3N7E#"R]XQD>>^2+(UNHI$DO[DM2?P?)/G=04ET;JF1(%T' M!:EU9LWR,Z?2U68CV$P41[)6O0MM)H,C:6N]_6TFA2,IJX'E;J:'(UEJD]-O M)H8CB:KIQH*9*(ZDJ=?M8)A)XTBZ6K]U8B:%(VEJS;:-F0Z.9*?->T5F?IE3 M6:G!SI29*HZDI36[8F8Z.)*7&NS$G>W"A!>20,/?/YY*Y(_\1S;<^1=02P,$ M% @ G4-I4SU*3XNR$P OW8 !, !A]_T))-UJXR1X,OL,=5#,8..^.C@&13[YV3B>X'\6!@I-6Z4RW=W=Z6[ M6BD4P[)5K]?+$YQ3,),:@@TR$R>V\/34:J6R7X;19"(.N'PV-SO/#"93 \H= MF9TIF5,:AK=E/03/5*WTNGPI"+4R#Z2B@<-F\Z6;AQG,MAO$Y/(#B5+#A2C46^\.!( M1G;N<24K.CAL4SD3'2[#W:IU\)"PF1DS-JSF09;^6@]4KI+L&2515/QY',5"G4?9K ESGTH(+>9EB$7R"K]5S+JM0+)\E,#J'Y?-T(>?8-;?BD5RS@(FJ&(NL:>D;V3K%&2+7(=" M48\4B665ZWH/8C6J^XU:C5Q?D&+QY,.QSQ0E"%&1_15Q@*X5!HH%JM@'Q2@0 MQWSZ6%!LHLK&Y91/CLL&R&,[=*=$JJD'D$K)XL$1 ;;(4#0(C51X M!&1Q^6VRD\OEV*.P*-A.5CCYOP_'?-) B)A(/G#794'\ 69=&@4WZ$Q4%]VE MB_0X_%P@ 44U!'%O-'T6N/!'G7ET6#@94$^RXW)FB8W7; ? K6D+%A74ZP!K M)I_9M'!2 :W?]?S[5>#?U)XI,J8IMT"RHSFM M-*GTQULJ. T4J!I$;-X1,K%(/3X,&@[(%Q-'\985W"W^4ZOE$7H)$&01BGLL M(QE 2 P)28%"8EA(6DC ^MDGOU]V^NU3TNLW^^W><=D^>5UP>NW6[]U.O]/N MD>;E*6G_V?JM>7G>)JVKBXM.K]>YNGQ]&/_5[/W6N3SO7UWND--2JT2JE;W= M^CIP?5UYFBM2'EI/5*[JWH.ZC.[UGFJ]E(5Z%2DXN^I>D,U\]FGH1!@&Z!@( MUS@L?C9BDW75[Z*T4I1^,"L-1K';ONR3;OOZJMM?1S[^L0#//]8ARYP(;P3O M:XC6(WB,J)#TF(,%$6+52"B(M;?E;K^^+P@'1(T8PA8)KCALU(9$C@9#1IJ. M(C!LU6N[/P[#,,Q%K+ML#$DBV4H^,PI!+I.*L%MXE @]S-SMQEHFU%3#/A;X M1#5<6-&'22.73J>P+ OR3.RUCJ_;)N[6D%V&M\RW(7FH[Q!<]\T9WNJ[X7V0 M%*\@SX_(R+MLR"66<-4EC&C):T+JS&_9#ND$3BE?[%Y39;?:$PJF"A$QFIL@ M0*@DO3%S,&UV"0](1TG2&D'>R\1:IO?93=KWI@TYLG^0B[BBML=BX#X6(&EU MF.?%Y:W99SFF3O+YJ<6S'2-S.T2"A ZR*75!EPA_.E98ICLY5@(^XT M7*O]DBN"ZRE6RN;C*0T67!0;B_ 6!35K](WF@7:% MR*/C;IX>R6*06W0MFD$U?('$V_ M%(35_>*N5=G?KU<> A%^:CG($8=\*,'P:"9A,'<%,90@_X002KI<1WEFJ_O8 M+UVK%?H^E_(QCW:Z/=+VQUXX92+]\"-0 ON9$P, M]$J_A9%4B37)HKBS:=*RG@.+X=!6\4I!'&V00B1PK4<-GW(619LK1&S+G1 MM2PZ!B,%*H:QF1U.B,V\\(YP4^@Z@X?)8?$S&>B&$L(E$$BQP(4,485$;XW-H.#F& M=Y)L2<;BY@0/PBUX-M(QHR3-4K5DX-UN?'7^/#9',P&]SJPV"+Y6)F$0H"@( M!;U$&U0XGJ5Q-9/$P?P7(\YC/*0=AIY-@>. U"1M8_XEN (APQ@_"N+X5B(# MZ@>[NT=+(I"?=,A[+WI^B"[U@U6$>5)(#&O'F ]TJB0<:K.W8U C':K>[$V M+)27L:J\91V0UEF75&N5$DSHT5=[><];@>S]U^0P;QQ?9)A4HFL6 "4I-Q7A^! MUIHXT0":?3L9P^N>ZE27'3PL-P/)/@\;B]4G&_9)7U"DSK+2^,8;;6" 5N ? M\[%HATJ%OCZ%)!(B')>(H;U5V2'XWW:,!3;:F[8(9T0U+=# M;TLN/7[XZA!=QB?3FE@LL7*@P7];)&)O;1[,CRI?3I(W0BY7.2(9I:>@V M_]CPP/)K@+SHWE%8[E?;$VXE#G/6J'%)I4O_(N=>"#$!^ D// 6YH.*&J36. M/M^@.WVFVF G<#$287@/R-%U0AB_ ?5C^MQVH8C'):$!@3 &EQB2H0COU @# MFC$6]J@D+AOPP'24F%I'98_<[Z.;M\_5R-:O/UO[!T=8J*W5CW39(WD&=@,N MCK$E!4^237!4M8O5G"7S6O,6U\9X:?YX:O72=U;P;2]AT+.&T>:\*=GJ7._4 M,ANMRLZ^%SIW!@^H QXOY.H6OU<;'X'F:(L$FA.$.I*-)-.S@#]Q!1ZO#G,= MW9H+1L@IO9 [TD08.UE^HH^]/XF2\S^E2X4I3 M>W>7A=&U+3H+H],:5B(S!C][1V5.F\'^>G>77N NT8-WEU[@KM1Z=Y=>1$UT MJ/JQ<'W^Z7-AT;]KB,T"18\-5'S/(_Y&&'+ 5X63A;7.^MW98GFA8FJ#A6=' M@R*HT_TO,6\BU^>7OU\L8)']D>;7=?.\7?S4;3<_%YMG_7:W0:AW1Z=RD0D9 M;!,F5S=B\IQM,Q+\=II/ J3CHPG0OVI]P76T; =2C&?')0J5LD<\N*VZ?]C&P\;1IXYC#P[):=<.EXH(\%*;^F M]ZFDN,)6L&SO^P[)]"23+;3=& %5*T>Q>]:?K*-M".=D!*:?@A? ]@L!/HB" MWZ%! **-E0DP_%2ACZ,VNBH(K?0]K!!R4&_H / ;^D:L/ M>IM_?"KV]HM[E0J&A."M;'!'FBG:7SG4#O]+T2=QF]PR\$ R^QWU\+P>'AW# M4V S9.SGW%M\(8$+:L$@T=(J(5@ 3D[_U:$"H >*0AP;@G>]16_K," *^$.! M1,475H!+951A22XFB,&6HS\&%"+;Q_,\??:M@\W0X4Q-M=OM8 4OQ B9CC6> M+01'D*U>I]_:-J@&0>Q%-<0<0*_M'\MHO*1RB(5#A*H8&QZKFAP,:'E VZI& MQV58X(0T@R "7"\8T][\CF(5T?:X'#'WS<2R3Y7MINX'^F?D30E*M9%MB7=, MYL(PXRKP#6470G_@JQM*752P89J@$X>!0]U"200QW";6'O&'Y9OA2H&$W?@D M)7A,8&5B&&J]2$1G![0#@RP0L>Q,AMF_+@*BP#!L8:+.M 3ZJN$#"?3-^9@* M)_JHC"5;V&!];TT.99HK!."E1H*E%TTV*Y$^^*'A"-"_99Y$0CA3!Q,EXM(I M(JL7!;1N34#I VH^ME<9B'B(*A<&CG[;@";$[#Z]5A9?/Y6R'-;!D21^Z#(/ M(,1L >:Y(AI"[@<0A&-=X]:-)M09&?( 0I%/SIN]_01,#13(LC8\&'U"1"M0 MTPSP50-\">PX07O=)#9>, (GUR2T M:A$'$E$\YRR!V258YT5: OH [FQK%V\WH2'59B7R83V7.4(;74UJW!.-P+>L MQ*FPX#\1T&TP7=!K$+?QK NHF3@62,<'D0BT#3,F%[YIZ1>MJ.3*&?KRI$F) M8LX_XC:8ZWH=>X/ZL-JB'W/GZU,0.)NAPLVWT;(Y0A9AUF6#Y6#,GWNW 0=7 ME_@&U&($&/*D,>BO%IDX3S*DM [7+$OL(.S4-VE=VCVG)R<^>@=S.>UI[B"= M0Z_T'ZQC%IW,$"+]IBS'8GFE781\84TA9L+^PNS94D M)P.& =] D0&22<]P"!B Y9)D5&Y*X% MO\7T/D6/+UPE+7!=AO2>4ZB^EZ507!V815D0/RB*V&*/L*_M!19HJ*ZGH0" M\&HI3J0S%'>0PA>],+R!11)H@9.F< =1&^ .-@N#C._9H*!$Q#*@NQ"-$E*E MP/\P-V-A4,TQFG7C^R3(D)B929L*5]HVH>"G-29F@)&_],"<1[&_3N\G(Q] M75R)JL7>2M!'6$>"YQ7SA9)7Z TX"F8J?4PE=T^EM_90XN.VJA-'#8O*"^: MOYF"SB_99&Q2K]V:I0LX7YLB$VTZ2:(02ZM&+ 6#+FOYU#6&V >'[M.;V-$I M$ -->?P)BI_5Z+3),Q1/EM1&2,$RR$OB1L@LD6X\Q=+9V(WO'ID:F(;I 98] M:"#0@ZN1CK# JB 2;DADF(,%((M!/@@UV H=!-G@RR'<30ILD)IC[$)/.!A9--7:(X M+%6L^ 9<9RZ ;ZD"\0*D?K!(]+QTSJU_&,33ANB]SO%>YWC7H%P->J^RO%=9 M?M@J2\[!P1LQ*L]U1E)_\(SD;'8VW)LGG28KT%FT_*X.2[;<[31BWP=2_8- T.Z;$O"B:3?Y=J^SNUO?QG>(SG<0VL2*$I)@W-6(+ M9.X]0*[5C7,M5WOC^R]JH^MT];ZJ4N'IPF:B_=ST?V;L5M53%]B]M[>W#KN; M/T+F;.3U.77:JNR^ADBU,,@GUWBJT<%.+& <)E>G5%&BWU.TA7KJ8F$9R1DG M21W]BSX(_J:/6?GQ"3>/GOD=@^]M;>]M;=]66]L*:<8;.YWSRV;_]^YZ[V__ M5I*6ZX6#5(&_2$3$^>?FA^@[>?W4+A8:'!I)?7K*97QT$I^V2:!Y7'> +6TV MHMX SZ%P(7W&%$_ 4[\(#\+UP MS0T8P:H"Z8*/A5IA'>CWOD+&@M>].G^T=TCGLE7Z2FECZB5-SW==W; Z)RAZ M#-&?Y>KZ-P31NDGZ2TK%IVGC27G6BEN(#^+V\J499'@F7G*9$[])M&%<#L;6 M,+,LR^2<'UI]OK%>2*9F^@^:P*; %_B=''WQ!X M\C]02P,$% @ G4-I4[4%02HK$@ TD, T !E>%\S,#0T.38N:'1M M[5QMHGJ&$EV=+$=E:3-[;W_[O1?OMS?Z^';HZWP$-_^K=L5;U6AK/0J%:.YN)Y61:KLJB,'VP*U*39$8@JO"JSV*E/EU!3JN\)L'#\_V@HD'XU,.A?.SS-^ MO?!=IW]3!V+0+_VAX =CF>ML?B"^^;4R_O!:Y\J)#^I&7)I<%N'AH2AEFNIB M M% ?"ZLD4Q\=EWI2\!KP204O4UL1]NT+7MQW!3SK"*:O'D94%;]AK='QV.]4C M[<7^?F]PM#4Z/MJB5?A1'C__ M1^4XQ<>1AW2_7L^$CG$R$SW$9F)J;W2SG9 M$,XFK5]Q-BW\/:=G:OS8HJH962N=I;U7MKZS5WPPDU;+PA^(@A0VJ\DGTOTR M=PF45]E#OJZAE3,]4V)8%*8J$AQT89SV].C"JDSGNI!V+DXE[&%L32XNIM(I M,1B):QR7B;.9S"KIH::";WMD2?^/O\")MH@NP+[P)6O5G"6S$ M@G'T)!72"P:5*Y-HY>?8UXKS/*\*XZ= I'(NS!BT0ZZ6)%R!G?=*D;3^1":6 M3&CMX:MG+X[FDY<.CN>V3HH'14+H!0A.'^^0+';%YE[_'R\ ;5YCF1,RF6HU M(U'BF?6D4I!N:0HHV=&6C@JECX=0@MW%:]XJQOM4Y5CJ _C[*H?\4Y7@2[S. MZCK"ITP7BO=Z:I;9"H(1P&K$2*E"3-A79=ET"5IV?K\_K_18R/T>('4SEO"GB# M?W46TMGO,&P0!HAO_OYZ>S X%%'2'7%>)#VQ^4&Z5/YZ((:7PY]?=& =";18 M0^9=Y^5$0=B)@8>;XT;R4A9SJ/U,9:9DG;&R<"%LX1T]J%)L( Q*JO(Z<70? M;$4BTV/5]5.VJ(+>3QBPX+N\2>4<=QQ< [V/Y67M'PJ()VW\ O9>^(82<1PUI-J8IN)D-TLG:U<""C^YQ&LNHTDA6GT>!"^)9=2$)^P[(+ MX8])XT(VD^3RY.0%%N,Q\+QLXSGQ\0 XYVM[=>C$YM7Y-?;:V3MR5:-,,P7^ MZ;*"%B*"."00ZDX5A34'@^W^/UJ*3.& GQYM88/C%3>Q;%0[06]ZB'$;JFNI M@)4I-L_H (@$6J]SX>08?'1$B?@VEXGY"") F-B\^/'%XFDZ1Z3+3T])U6#2 MM;(!GG'5&J*@B^X]@EA?8) M4WEP":F312RS(].99'#XJ--"S2-X] 0$FQGSD=ZXD3:EW1STC?&)J2'X:/2, M<83W(Y)(LR&/*>MBKE)> @)@B:2+;*7:B3D6-79(9KAB/+THRJ]);8>.KNF_ M*\0/VX, !Y1CS%1+S:Q*E)X%.(.RL6M6'%>L7O%@5^23K8^3SZHQSM"WK9M' M#(!-)R:X&WB.',\#=HQ)%Y=7!HP?98KU1Y&>RF3> [+=&^W$(T9(G\ )$,^: M:C(%._!RCAA+YC D,1#DH< &+P?!%*M @V"X.B?O$L[2<,,4NU X8 .+.B6M M'VN(J?%?)\&7-CJ5FQ0N2Q=D_!2NV&I2^UGB5\@2YH$(-C .4JM[=5D M,E% =8)JAPU*J\$_+"$0OQV([R%.X.1I"&=$ES7C '$1!^/2[L3&-X@G:^G0 M[<7HNI$[A=D= ;>-@$TS]?*NY@#M*3Y.R?_^C];?5"LZ-3OV4-D'LMG'\ M_-GS9\^./)+39_0SK8^+J_9Y$0S[ ED3Q';1UH93Y>'672@!>*IQ/L-/VNHY M?A*?:XI57X%0!E@D5D)C0;$Q2^J:*KH';:'<*]=A.XU LI.:'+S0VBKE&)V2 MAZL]RA\^K]\@R)%W6-+YC#SFG="MB74^EV'<3)$ORYE:N&*8*21,J+?PERN7 M_QG)+:[^,])97O;0S4E78QYD'W8+E\I-P>NE+"8W,I,=\9Z#TQBCANCT?0S> M[L:F?S7F3X&3#^/[3C[V5V.%3/1AK+PZ@(4,WS=%""[87+P79]=_-9[>F80- M^&%\_4 !R=E#P+4-?'>*^ \I-MU?6DKU#$"!4.J[C8NWW_^X<8."> MR?*/YT=36Q]\,7Q[UOW^\FSX8W?XYOKL\@"@>2/G[C"Z(W+JA5KV$"+6/\0V M-5RH@(5E?^_S?WA/)A\G"/.+M+O\U1T!_'"Z7@"A;?-OLG_]T\D[77S\I #N M=I+^4!?H$]5Z8N612O5+&ON&HOT8Q\LZUY$AJB\SCMEGVNE6_/JE*EV!M]5H M6(UP&,0S];YT!UM;-SVY4>1/6#M9%%//R', M.E_(_W,=HC]Z>EW:#Z5#*N[+WU'>#Y[O4T7^4.59JO"$PN7J(3F2X!&2]R0) M6?((F0UR75*'S=>O7KT0+[=WNONO!SMB,Z4B%/3M!5.VN=T?O!![K_>[KW=? MX5NN>H8X3V9AB54X*A2=3/O@\U-X[U?;+P>#W9X8+G@$Y)\W&.AAX4E>\Z8M&N$&?24ZU1FO;D[$\A\!T*\B$JET<)]:4W#T2 MFZ_FF,WN8\HQUE#^-9C(<&2J #_KF\JM5(#K^J$Q_536 ^WV6L;FRMH&2/MY MT_584T5FVO'A/5<^%W7^^_9L+(MWI!815_B4P[.0ZW ZU!':"75;0C\55V%5 M80V9-M6N;C6P1F5S,7B]2'58MZWBBB%9CK2Y$YMUP8 ,/Y8.R,"VX^,7O'7H MY5"[D+J:(YWI-=T'=Z?SX.ZK68B%14$$WY<@LS8W:7"];R@UKLN%EW6]L1.< ME6GGPWNU /@KUYN8F?AP;*RYST/U%YQ*CXIP2A$5*X^@.>:1U?/*D/<>D6"I08:U6V MJ%F7ACJ.@(\"SBA ;-U,2!MTXL?-%CH/)(5[7%9C[.&YC1O"P1GA+R<^J^R& MHU8F)R#1GE@QE*0"P87/*(8E,=<^<$6)EK#;+1,\@9>B%]Y0X'=MD0:#1U95 M%FML2/^S=]43;XQ)^>53ZD4-4^ISN;JE1<^-A6\MZE;5G4W.*@LW*'D.+]?A M5LC,*&(HJKR1D">3#YS5FE[K]-<"LP2H\;1F#/*)HL8XY,,P^_1S/<'5QE[G ML@JWAG$(.Y'_+VW>63^B0R@#3@"?C2[*.L;:640K:Y1L6;4HAKT; 1246QFH M-@<,958!H#XW0\&FL'ZSL;9N-?@(+;,&O"7",M-L=D=I6N@A_ M=>M=7%B35H22K8;QD$BT+ZNT>08.$:K?I$[>:H.J8Z2BOM/-JJCI_2DO]3"_U/+?0O7PN% M'W@3II6Z[PQEJQ-QY0&>9+KNL5W#-4TTQ1FG&$]1(BMUX>H9JFX6J7(-51PD MQ6)4#K_.D6FL.5B$1D".*W+D8:;FG>;,E/:^5 068I@P^ WV]WUZ1W^0QI-$O%+2#?JO=Q[ EC?5:TC%6 M#X[M$[HHT%LY*LGZ*@P=\=P@%W<1^L/?2)X"HBGVZ,RHG!'U-3A'BHLT=-8[&K5B>AI4SY"V#,*[>^:D/ : M5$D&$SSYZ>?ST^Y@7X0$K0XXOG6BE3W23-5DWEE-)SH\9(;+2*92ASQ@#-=A MI78LPN7]VJ3>EB&C6H0HD*19[@BE$8_K6 MR5P6&LN9L5SMH M9>=+-AAL%>0%&9_HYMH](XT M0>4Z.0Q:#@L+XFN+EUHU 1K(B9/%.A!%4Y8$W71X7>XKJ2]88PI+0W BSY'N M.NG1UVSBG'EPT=02R0NAKA+6DBP3QC/<%/4M9*:Y9(-OBXJ@)=186PP="KU2 M87:1("X>!Y1QSB1Z49$@\N"Y/RK/+:N2ZPGM0DMI=<)U<\X'=#ZJK./[/&PK M2)M$19%[4CNAA;:0X\NHID4H'(4Z#W\:Z0Y7UM*X>AA0+T+NIA$".\.8LWZ? M,*Q;X"4ZN5 JC:DAB%%AM!?7I1'1T!8YH1W7_P)&W^LM^(;;SH+Q-R!AP!$1 MH@%&]1&[#2!;%494U>T4F_$\.[ORL')$!B?34 0K?@'H+XI@+1?:F'OT]"F" M;*LB(JK,J1OZO7U7C4;57#5OWC'=V*F^9-@G*;^A &K0[_[(_I^=B:;F"\^E MBU#R/P5<,/+OA)';?H<1!&(\B1X^[.>:#5]C/^:\&CE 2T9:[)FMW!!5V?B!BISJIXS8KGI[\"6$I*_FIW"E\"LYX_ MYM$RB8?^%] A2^HC0X'C\8[=W-W=?R%V=G>[VWNO=O[?:Z4^;L88'E];WE5 MC!^4G&3J*34EF_*13ZPG^P,DC'N#_>[NJ[V7CWG2?;6V=\.KZ^ZB.K6V>O9% MJV)U40@?Z!_!@"KQO^7Q?U!+ P04 " "=0VE3WJ!:_ 86;(X@)W: M;ULMJ6WU(*FUW2V#\^OW=$NR92! -F'&9)U*;*>EOGT?YSZZ[:M!:.+H:!!R M%AQM;@R,,!$_XC?_[K9V]_;V&K@Z:.:#FQNX_I=ZGAC+A;Q*Y=;0Y:.9,#SP9 MS$B;6>2F)Z:NQ6?>HW8K-7UR V,6BVC6H]?_R:3I7XJ8:_K$K^EL0R(_MVS;1<*&9J(I*Z)XV1,>:D-WTR_,;4 M620F28^4F(18OKC-R-3= UDM0TOR0YDJ,"U$6LH&6=W1Z M$PI/&#H\;'0&3>]HT+1WX2T]VOP*;B,^?FYF7R>>3OM?X*]*^P[I_H*6LZG[ M[Y0IP1+32RQ>HG[.>L]>7BSUY35N+?'5*T#S0QJ%3'-J>\T.*98$,L;\ *ME M@*,JT4 E"]C3R3,0IJNA0G)9Y[\#/HB$1Y-N=*97AYC$:!N MIZ:8!0?0^3P63%GB8R$_XDR1SZ.(%$_@=^ZCSY0O$@A%UZ&DD$TYKOI<3#%C MK*QXCA+ M+*)U"BE!((2%)V%)H)@0,U_)-&037@\4M)#@^CAB<>S@X<\NG2AH.'PQ@0^52$8-S)A/P"=48Q:PAL@C&47Q2:CF#E9V637G!AR$DDO@S?269N0RJ8SFQCQW^UW?FT'[BO\$+J+K3EMNM44(J=$,TJE MS8>(M"GWQ5CX;JF%!AH$P#"*908%.5S0#<=JBHT-1@,>[5 A->E07MN8A21@ M*4%PT(^E@F8SO$$H ,6I];X0EK+/,F65^+48<,&KX&04MKWEL&B73B,;\$+( M![THELY@D2("9W#8 =B%'DXE1WOWO8V=V'EA))@82DAC2%D-E#? M\!P7H!! 5:D+^IU\U>WS4>>D9J5J[U$\:5Y-W&P.SKU(Z# OD5BN]3I "._& M6*"RR9)7;'_\Y01T&& OF1\V7GK$NL2E"!):7+UX60" $0"8I2'=3"4A6,^K,FZ)^@BFN"TB9DDXRN_YC#AJ M7)$O1;X2!@4JFU.O9%98%6S)R8QLS+0$F;$I42,()4X\1!-7/>4\N*#%@AB+ M:A!U.G.\S76-^^W6!N$ AD9E;&R(>O'>?B3)&0L>"N0 M5,T_>8%3>"HX.&Z?8"EW%Q:9<-\.[CSDF[ M02.&Z,BB>65V2P[K&5VKK;V%#K8OD2017VI]5 O18KQ2\@1%&1+PO!S-6?;P MR;IAXW&,?&<J^W)J/JSY5%K@U-QS7E;R^.^@BVNCLTS\_+F3 '?;8 MI/JV.0A5N?!H>'9:?WM^.GQ?'[Z[/#WOP2[7;*;[Y$D5<-5#M97P)6;Z*%QS MJ3KV2,%'^,1MKUKN#^;-]V#UY4MW%/#WD_L5D!],_(_B7_YZ_$$D5P\J8*Z' M>_'SU><J!L[U';5;@Z^ I[EL>!6YL;FP, MC/K>O%C*EG!0$LY];WYTUTYO2,M(!*0FWC;J,OL7(10%F;&V+-%F9+KPFT[C M\*>G'X4^JJZ")7=.^"5^BGMR-2YN\B*$A(KA3? ,\NX>- Y63%XGY/TAYELX M6W(P*CRL&H+F_PX=MD;S&E97B]B\;LW=<#48+4OHYMWZV;%IN7P>\+3W&^TU M>.ZSR2LZGF&[I%<))]@1IQ%'I?@$5!0E2%7UA8I+ [C[>[GVYX,E+FR!\Q!P M.MW&_G<$SLJ8_2VW.QY(CBI]E4Q?;C5N6Q[OZNC_/CFO>"QIMSIUU)C/',N? MJ1!86=UV]^>;#I'8C7Z/ZNV#7.&UO.1Z^)4^B:F,LIAY39$*;!3LQ]5P^@=D MZSQ-MN&-< _7U999N*^'N]YT*58\:X.&-O9T_'C&/ M\[7XUJVHTE:,/_=-S3,C\SO7A@\CL[Q:'%BL8)[*:X"+DW7IMK+QYK'2K;,N MW5:L=!N5/[Y8^;+AB?7:B,>>@I4^NWJ4O93J;5WJ/'O*[NZ4WZ"N\_8Z;Z_S M]A/S=G=]Y+*">?M%'KFLD]RS)[G==9+[,[\I/=^A+/%E,A;V-[OKC+>RGO10 MQMM;[U17,.-=9$F^EZ-.;9'^UCEOG?,ZZYRWSGGKG/=-.>]OZYRW@CGOASN= M/04^I-VNKLCOP9[P??J/\ON W1_X8&'O6[X;H&WW8[5%>["<_\1U=%);>=G7 M!>:ZP%P7F!N;>+>M(']J=^%+Z&"\R&+;<-M[Z7*4+90/=3B[IPHL/0TA53(6 MVG91II6>ICL]P'?:C>_V1A&^3XW=M7BQ[ M]_#!/@/J:-!T#[/Z+U!+ 0(4 Q0 ( )U#:5.N N4_;@, "<. 1 M " 0 !A&UL4$L! A0#% @ G4-I M4Y)U4_. ! -2\ !4 ( !^0X &%R878M,C R,3$Q,#E? M<')E+GAM;%!+ 0(4 Q0 ( )U#:5,]2D^+LA, +]V 3 M " :P3 !A